The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A supervised prehabilitation program for patients with pancreatic cancer.
 
Philip Chang
No Relationships to Disclose
 
Arash Asher
No Relationships to Disclose
 
Andrew Hendifar
Consulting or Advisory Role - Amgen; Exelixis; Exelixis; Exelixis; Faraday Pharmaceuticals; Ipsen; Merus; Novartis; Pancreatic Cancer Action Network; Regeneron; Valar Labs; Varian Medical Systems
Research Funding - Ipsen; NGM Biopharmaceuticals (Inst)
Travel, Accommodations, Expenses - Halozyme
Other Relationship - Rayzebio
 
Gillian Gresham
No Relationships to Disclose
 
Novalyn Cruz
No Relationships to Disclose
 
Jun Gong
Honoraria - Agenus; Amgen; Astellas Pharma; AVEO; Basilea Pharmaceutical; Bayer; BeiGene; Clinical Congress Consultants; Eisai; Elsevier; EMD Serono; Exelixis; HalioDx; Incyte; Janssen Biotech; Natera; Pfizer; Pfizer/Myovant; QED Therapeutics; Seagen; Taiho Pharmaceutical
Consulting or Advisory Role - Agenus; Amgen; Astellas Pharma; AVEO; Basilea; Bayer; BeiGene; Caper Labs; Clinical Congress Consultants; Eisai; Elsevier; EMD Serono/Merck; Exelixis; HalioDx; Incyte; Janssen Biotech; MJH Life Sciences; Natera; OncLive/MJH Life Sciences; Pfizer; Pfizer/Myovant; QED Therapeutics; Seagen; Taiho Pharmaceutical
Patents, Royalties, Other Intellectual Property - PCT/US2021/043961 provisional patent on glutamine and cancer; U.S. Provisional Application Serial No. 63/315,895 on methylated ctDNA markers